Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 7,248 matching trials from the live ClinicalTrials.gov search.

Filters: Detroit, Michigan Clear all

Conditions: Glioblastoma
Interventions: INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide; Biological · Radiation · Drug
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 21
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 15 more

Conditions: Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Interventions: Tonlamarsen, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 10 more

Conditions: Heavy Drinking
Interventions: Motivational Interview with Self-Talk Video, Motivational Interviewing; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV Infections
Interventions: tipranavir, ritonavir, saquinavir, amprenavir, lopinavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 34
States / cities: Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 28 more

Conditions: Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
Interventions: RP6530; Drug
Lead sponsor: Rhizen Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Duarte, California • Orange, California • Aurora, Colorado + 5 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Interventions: defined green tea catechin extract, gene expression analysis, protein analysis, laboratory biomarker analysis; Dietary Supplement · Genetic · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Intracranial Arteriosclerosis, Stroke
Interventions: Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years and older
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 114
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more

Conditions: Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions: NBTXR3, SABR, Nivolumab, Pembrolizumab; Drug · Radiation
Lead sponsor: Nanobiotix; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 13
States / cities: San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more

Conditions: Liver Transplantation
Interventions: Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 829
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more

Conditions: Hodgkin Lymphoma
Interventions: Everolimus (RAD001); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 16
States / cities: Los Angeles, California • Greenwood Village, Colorado • Orlando, Florida + 13 more

Conditions: Blood Pressure, Heart Disease, Hypertension (HTN), Blood Pressure Monitoring
Interventions: Model BB-613WP; Device
Lead sponsor: Biobeat Technologies Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 3 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 28 more

Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions: Alisertib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 50
States / cities: Hartford, Connecticut • New Britain, Connecticut • Orlando, Florida + 37 more

Conditions: Stroke, Transient Ischemic Attack
Interventions: Rosuvastatin; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 30 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Solid Tumor
Interventions: 68Ga-FAP-2286, 177Lu-FAP-2286; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 16 more

Conditions: Obesity, Overweight, Blood Pressure, Hypercholesteremia, Diabetes
Interventions: Motivational interviewing to elicit PCO in pediatrics; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 2 Years to 18 Years
Enrollment: 703 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Coronary Artery Disease, Coronary Artery Chronic Total Occlusion
Interventions: Crossing of Coronary Artery CTO; Device
Lead sponsor: Asahi Intecc USA Inc; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Phoenix, Arizona • Loveland, Colorado • Atlanta, Georgia + 8 more

Conditions: Glioblastoma, Recurrent Glioblastoma
Interventions: Adavosertib, Radiation Therapy, Temozolomide; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more

Conditions: Newly-diagnosed Cancers, Non-cancer Controls
Interventions: Freenome Test; Diagnostic Test
Lead sponsor: Freenome Holdings Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 788 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Cordele, Georgia • Orland Park, Illinois • Park Ridge, Illinois + 20 more

Conditions: Immunoglobulin G4 Related Disease
Interventions: Rilzabrutinib, Placebo, Glucocorticoid; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 21
States / cities: Fontana, California • Sacramento, California • San Jose, California + 18 more

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more

Conditions: Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Bronchopulmonary Dysplasia (BPD), Anemia
Interventions: Liberal Cell Transfusion, Restricted red cell transfusion; Procedure
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 48 Hours
Enrollment: 1,824 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Hepatocellular Cancer
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 52
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Search by objective public record fields.

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

Increasing Effectiveness of an Alcohol Use Reduction Exercise Using Self-Talk Videos

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

PREVENT ALL ALS Study

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Rosuvastatin in African Americans With Cerebrovascular Disease

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes

The Asahi Intecc PTCA Chronic Total Occlusion Study

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Transfusion of Prematures Trial

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC